H4-CBD
| |
| Names | |
|---|---|
| IUPAC name
2-(2-Isopropyl-5-methylcyclohexyl)-5-pentylbenzene-1,3-diol
| |
Other names
| |
| Identifiers | |
3D model (
JSmol ) |
|
| ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C21H34O2 | |
| Molar mass | 318.501 g·mol−1 |
| Related compounds | |
Related compounds
|
H2-CBD |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
H4CBD (hydrogenated CBD, tetrahydrocannabidiol) is a
H2-CBD and 8,9-dihydrocannabidiol have also been referred to as "hydrogenated CBD", which may cause confusion.
Pharmacology
In 2006, it was discovered that H4CBD has a binding affinity of 145 nM at the
CB1 receptor and potential anti-inflammatory effects independent of its cannabinoid receptor action.[2] In contrast, CBD has been found to bind to the CB1 receptor as an inverse agonist/antagonist with a Ki ranging from 3.3 to 4.8 mM.[3]
Elucidation
In 2023 H4CBD epimers were elucidated using
COSY NMR spectroscopic techniques, while the inclusion of LC-MS and SCFC were used to isolate individual diasteromers.[4]
See also
- H2-CBD (also hydrogenated CBD)
- H2CBD)
- THC)
- 4'-Fluorocannabidiol
- 7-Hydroxycannabidiol
- Abnormal cannabidiol
- Cannabidiol dimethyl ether
- Delta-6-cannabidiol
References
- .
- PMID 16451075.
- ^ "A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)". Basic & Clinical Pharmacology & Toxicology. January 2022.
- .